IRIS - Res&Arch Institutional Research Information System - Research & Archive

BOLLI, Geremia Brunetto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.567
EU - Europa 5.178
AS - Asia 3.464
SA - Sud America 638
AF - Africa 56
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 8
Totale 14.931
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.482
SG - Singapore 1.662
UA - Ucraina 1.086
IE - Irlanda 831
SE - Svezia 746
RU - Federazione Russa 612
IT - Italia 573
BR - Brasile 553
CN - Cina 532
HK - Hong Kong 485
DE - Germania 380
VN - Vietnam 320
FI - Finlandia 318
FR - Francia 214
GB - Regno Unito 168
KR - Corea 138
TR - Turchia 135
AT - Austria 52
PL - Polonia 51
CA - Canada 42
AR - Argentina 34
JP - Giappone 31
MX - Messico 30
CH - Svizzera 29
IN - India 29
NL - Olanda 26
CZ - Repubblica Ceca 22
ZA - Sudafrica 21
UZ - Uzbekistan 19
AU - Australia 18
BD - Bangladesh 17
IQ - Iraq 17
BE - Belgio 15
EC - Ecuador 14
ES - Italia 12
ID - Indonesia 12
PE - Perù 12
GR - Grecia 10
MA - Marocco 9
LB - Libano 8
PH - Filippine 8
PY - Paraguay 8
RO - Romania 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
LT - Lituania 6
SA - Arabia Saudita 6
CO - Colombia 5
EG - Egitto 5
EU - Europa 5
KE - Kenya 5
MY - Malesia 5
PK - Pakistan 5
AZ - Azerbaigian 4
CL - Cile 4
JO - Giordania 4
KG - Kirghizistan 4
NP - Nepal 4
RS - Serbia 4
UY - Uruguay 4
EE - Estonia 3
IL - Israele 3
JM - Giamaica 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DK - Danimarca 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
TH - Thailandia 2
TN - Tunisia 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
KH - Cambogia 1
LU - Lussemburgo 1
NE - Niger 1
NG - Nigeria 1
PA - Panama 1
SD - Sudan 1
SI - Slovenia 1
SR - Suriname 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
ZW - Zimbabwe 1
Totale 14.931
Salva come PNG Salva come JPEG
Città #
Singapore 1.003
Dublin 831
Chandler 772
Jacksonville 582
San Mateo 537
Hong Kong 483
Boardman 330
Santa Clara 265
Medford 248
Princeton 246
Altamura 206
Dong Ket 192
Ashburn 189
Wilmington 184
Moscow 170
Lawrence 146
Seoul 137
Andover 120
Izmir 112
Perugia 111
Beijing 105
Munich 105
Ann Arbor 104
Des Moines 101
New York 88
Los Angeles 79
Saint Petersburg 78
Helsinki 71
Piscataway 55
Ho Chi Minh City 52
Norwalk 43
São Paulo 41
Rome 38
Woodbridge 36
Brooklyn 32
Chicago 30
Shanghai 30
Turku 29
Warsaw 28
Tokyo 26
Falls Church 24
Fremont 24
Nuremberg 23
Hanoi 22
The Dalles 22
Milan 21
Belo Horizonte 20
Frankfurt am Main 20
Vienna 18
Amelia 17
Dallas 17
San Paolo di Civitate 16
Brussels 15
Stockholm 15
Changsha 14
Denver 14
Rio de Janeiro 14
Bologna 13
Porto Alegre 13
San Francisco 13
Amsterdam 12
Ankara 12
Atlanta 12
Falkenstein 12
Brno 11
Campinas 11
Montreal 11
Poplar 11
Tianjin 11
Auburn Hills 10
Boston 10
London 10
Bexley 9
Den Haag 9
Guangzhou 9
Brasília 8
Goiânia 8
Houston 8
Manchester 8
Mexico City 8
Orem 8
Phoenix 8
Redmond 8
Tashkent 8
Chennai 7
Frankfurt Am Main 7
Guarulhos 7
Haiphong 7
Hải Dương 7
Melbourne 7
Terni 7
Baghdad 6
Charlotte 6
Columbus 6
Guayaquil 6
Johannesburg 6
Mumbai 6
Olomouc 6
Ottawa 6
Toronto 6
Totale 8.725
Salva come PNG Salva come JPEG
Nome #
Ipoglicemia da iperinsulinismo organico: un caso di nesidioblastosi dell’adulto. 198
Adrenaline vs glucagon in the primacy of glucose counterregulation 147
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 138
Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. 134
Hypoglycemia 131
Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. 129
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 128
Alternative routes of insulin delivery 116
18. Insulin required for prandial ghrelin suppression in humans 113
A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. 109
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 108
Aspetti attuali del Diabete Mellito 2002 105
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 105
Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. 104
[Behavior of plasma androgens in cases of adrenal pathology]. 104
Adrenergic activity and glycometabolic compensation in patients with diabetes mellitus]. 103
Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus 102
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 101
Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. 100
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 98
Contribution of amino acids and insulin to protein anabolism during meal absorption. 98
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 97
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment. 97
A novel surrogate index for hepatic insulin resistance. 96
Insulin is required for prandial ghrelin suppression in humans 96
Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus 96
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 95
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 95
Intensive insulin treatment in diabetic children 94
[Effects of circulating anti-insulin antibodies on the kinetics of injected insulin in type I diabetes mellitus]. 93
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 91
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 91
Analysis of short-term changes in reversibly and irreversibly glycosylated haemoglobin A I: Relevance to diabetes mellitus 90
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 89
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 88
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 88
Nocturnal blood glucose control in type I diabetes mellitus. 87
Insulin treatment and its complications 85
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 85
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 82
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 82
The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity 82
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 82
Impiego dell’analogo dell’insulina glargine in una paziente affetta da diabete di tipo 2 con grave resistenza insulinica. 81
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 79
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial 78
Il nuovo analogo dell’insulina ad azione ritardata glargine: caratteristiche ed uso terapeutico nel diabete mellito 77
Treatment and prevention of hypoglycemia and its unawareness in Type 1 diabetes mellitus 77
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 77
Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. 77
Glucagon: the effects of its excess and deficiency on insulin action 77
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. 77
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 77
Establishing the deficiency of glucagon response to hypoglycemia in humans 77
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 76
A case of neoplastic hemorrhagic pericarditis. 76
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 76
Clinical strategies for controlling peaks and valleys: type 1 diabetes 75
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. 75
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). 75
Rational use of insulin analogues in the treatment of Type 1 diabetes mellitus 74
Glucose variability and complications. 74
COMPARISON OF VILDAGLIPTIN AND PIOGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN. 74
Insulins today and beyond 74
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 74
Glucose variability and complications. 73
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 73
Hyperglycemia alters the physico-chemical properties of proteins in erythrocyte membranes of diabetic patients 73
Chloroquine reduces whole body proteolysis in humans 73
La resistenza insulinica nel diabete mellito di tipo I Effetti della terapia insulinica intensiva 73
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 72
Insulin treatment in type 1 diabetes. 71
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 71
Erythrocyte concentration of glycolytic phosphorylated intermediates and adenosine nucleotides in subjects with diabetes mellitus. 71
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 71
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 71
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 70
HYPERGLYCEMIA-INDUCED PLATELET ACTIVATION IN TYPE 2 DIABETES MELLITUS IS RESISTANT TO ASPIRIN BUT NOT TO A NITRIC OXIDE-DONATING AGENT. 70
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 70
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 69
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. 68
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 68
The effect of menopause on carotid artery remodelling, insulin sensitivity, and plasma adiponectin in healthy women. 67
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 66
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. 65
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 65
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 65
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 65
Quando “i conti non tornano” (Caso clinico) G It Diabetol Metab 26:172-175 64
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 64
Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus 64
Terapia insulinica moderna 63
Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. 63
Opinioni a confronto: quando e come usare il microinfusore rispetto alla terapia insulinica multi-iniettiva nella terapia intensiva del diabete mellito tipo 1. 63
Kinetic behaviour of the glucose-hemoglobin labile adduct in normal and diabetic erythrocytes. 63
ROLE OF PANCREATIC BETA-CELL FUNCTION ON A-CELL RESPONSE TO HYPOGLYCEMIA IN MAN 63
Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. 63
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 63
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 63
THE CATECHOLAMINE CONTRIBUTION TO HYPOGLYCEMIA IN IDDMDiabetes 62
Totale 8.487
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.105 0 0 0 0 0 163 158 15 264 74 193 238
2021/20221.843 42 332 46 130 52 16 10 642 18 52 210 293
2022/20232.836 259 486 38 201 204 346 6 117 1.064 7 85 23
2023/20241.090 72 122 50 19 15 10 208 24 101 52 216 201
2024/20252.731 19 313 58 132 424 53 59 230 690 173 322 258
2025/20262.797 460 347 344 721 784 141 0 0 0 0 0 0
Totale 15.339